Goldman Sachs issued a research report stating that GENSCRIPT BIO (01548) delivered mixed results in the first half of fiscal 2025, with gross margins remaining under pressure. However, business sales excluding Legend Biotech largely met expectations. Management slightly raised the 2025 guidance for the life sciences business from 10%-15% to 13%-15%, expecting the segment to maintain steady growth.

Goldman Sachs maintains its "Buy" rating on GENSCRIPT BIO while reducing the target price from HK$27.34 to HK$26.25. The firm revised its 2025-2027 earnings per share forecasts from $0.07, $0.05, and $0.10 to losses of $0.03 and $0.01 for 2025 and 2026 respectively, followed by a profit of $0.03 in 2027, reflecting continued pressure on profitability.